AB ENZYMES GMBH

Their core work

AB Enzymes is a German industrial enzyme company based in Darmstadt, specializing in enzyme development and production for industrial applications. Their H2020 work spans bioprocessing of cereal side-streams, cellulose-based materials, microbial expression systems for biotherapeutics, and enzyme-driven plastic biodegradation. They bring deep expertise in recombinant protein production and microbial fermentation to EU consortia, serving as an industry partner that bridges laboratory biotechnology with commercial enzyme manufacturing.

What they specialise in

How they've shifted over time

AB Enzymes' early H2020 participation (2015–2017) focused on valorising agricultural and forestry biomass — extracting proteins from cereal side-streams (PROMINENT) and developing cellulose-based materials (NeoCel). From 2019 onward, they shifted toward advanced bioprocessing platforms: engineering microbial expression hosts for biotherapeutics (Secreters) and applying synthetic biology to plastic waste biodegradation (MIX-UP). The trajectory shows a clear move from biomass processing toward synthetic biology and circular economy applications.

AB Enzymes is moving from traditional biomass processing toward synthetic biology platforms — expect future involvement in bio-upcycling, engineered microbial systems, and circular bioeconomy projects.

How they like to work

AB Enzymes participates exclusively as a consortium partner, never coordinating — consistent with a company that contributes specialized industrial enzyme expertise rather than driving the research agenda. With 50 unique partners across 17 countries in just 4 projects, they operate in large, diverse consortia typical of BBI-RIA and RIA funding schemes. This makes them an accessible partner: experienced in multi-national projects, comfortable in supporting roles, and likely easy to integrate into new consortia.

Despite only 4 projects, AB Enzymes has built a broad network of 50 partners across 17 countries, reflecting participation in large BBI and RIA consortia. Their reach is thoroughly pan-European with no obvious geographic concentration.

What sets them apart

AB Enzymes occupies a specific niche: they are an established industrial enzyme manufacturer that actively engages in EU research, bridging the gap between academic biotechnology and commercial-scale enzyme production. Unlike university labs, they can validate enzyme candidates against real manufacturing constraints. For consortium builders, they offer a credible industry partner with hands-on fermentation and bioprocessing scale-up capability — particularly valuable for projects that need to demonstrate industrial relevance.

Highlights from their portfolio

• MIX-UP
  Addresses the plastic crisis through microbial biodegradation and upcycling of mixed plastics into PHA bioplastics — a high-visibility circular economy topic with strong industry relevance.
• Secreters
  Largest funded project (EUR 252,788) developing next-generation microbial expression hosts, directly aligned with AB Enzymes' core business in industrial enzyme and biotherapeutics production.
• PROMINENT
  Earliest project representing AB Enzymes' entry into H2020, focused on extracting value from cereal processing waste — a practical food industry application.